Patients who have cancer will be treated with Phase III protocols of the Southwest Oncology Group in an interdisciplinary approach utilizing surgery, radiotherapy, chemotherapy (which includes variable schedules and combinations of drugs, including both investigational agents and already proven and accepted drugs, either alone or in combination with radiotherapy; these forms of therapy would represent the current most effective drug combinations identified by group studies), and immunotherapy. Patients who are unresponsive to the above therapy will be managed with new experimental agents, which have been carefully evaluated for dosage and toxicity, and which show suggestive evidence of anti-tumor effect in specific malignancies. These will represent the Phase II protocol studies of the Southwest Oncology Group. Patients in relapse of their disease unresponsive to Phase III and Phase II protocol agents will be treated with new experimental drugs for possible anti-tumor effect and for evaluation of maximum tolerable dosage and careful evaluation of human toxicity. These protocols likewise will be those of the Phase I Southwest Oncology Group studies. Both pilot and independent protocols will be prepared and evaluated in conjunction with Southwest Oncology Group studies. Ancillary studies utilizing patient material being evalated in the above protocols will be coordinated with research activities of other departments in the areas of pathology, immunology, biochemistry, pharmacology, and anatomy through independent grant support.
NIH ExPorter
NIH ExPorter